Regenxbio, a startup company co-founded by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor at Penn Medicine, reported long-term data demonstrating that its experimental treatment for Hunter syndrome, a rare genetic disorder, lowered levels of a key disease activity biomarker. Read more here.